| INTRODUCTION
The percent of donors labeled increased risk for disease transmission (IRD) has increased from 10% in 2010 to 19 .5% in 2015. 1 By definition, organs recovered from IRD donors maintain a low, but non-zero 2-4 risk of disease transmission ranging from <1 in 1000 for hepatitis C to <1 in 10 000 for HIV, 5 ,6 yet they are more likely to be recovered from younger and healthier donors. 1 While IRD kidneys can engender administrative burden through consent documentation, 7 medico-legal worries, patient concerns, 8, 9 and recipient tracking and retesting, the pool of donors labeled IRD continues to grow as the national drug overdose epidemic persists and infiltrates deceased donor transplantation. 10 Understanding the risks and benefits associated with acceptance of IRD kidneys is necessary as these organs continue to be offered to (and declined by) candidates on the deceased donor kidney transplant (DDKT) waitlist.
Unfortunately, the risks associated with IRD kidney transplantation remain controversial. Studies have shown similar [11] [12] [13] and higher 14 risk of mortality and reduced 11 and similar 12, 14 risk of graft failure associated with IRD versus standard criteria donor (SCD) kidney transplants.
However, candidates on the waitlist do not have the opportunity to choose between simultaneous offers of an IRD kidney and a similar non-IRD kidney. Rather, candidates must decide whether to accept an IRD kidney now or wait for a non-IRD kidney in the future. Through simulation data, our group identified patient subgroups that might benefit from IRD kidney transplants 15 ; however, we were unable to identify candidates who were offered IRD kidneys or to determine the consequences of declining an IRD kidney using observational data.
Furthermore, donors labeled IRD are more likely to be younger, have anoxia as cause of death, and less likely to be classified as extended criteria donors, 1 and it is important to understand these donor factors in the context of survival benefit.
To better understand IRD acceptance practices and the impact of these clinical decisions, we used national registry data to study patients who declined an IRD kidney, the natural history of the decision to accept or decline these kidneys, and the survival benefit associated with accepting an IRD kidney.
| METHODS

| Data source
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, wait-listed candidates, and transplant recipients in the United
States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere. 16 The Health Resources and Services Administration, US Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. 
| Definition of Public Health Service increased infectious risk donor
| Subsequent outcomes following IRD kidney decline
To understand the consequences of declining an IRD kidney offer, we followed 101 972 candidates who ever declined an IRD offer 
| Survival benefit of IRD kidney acceptance
To characterize survival benefit associated with accepting an IRD kidney, we identified 5702 candidates who accepted and were trans- Candidates who accepted the IRD kidney at the initial offer (n = 819) (ie they were the first to receive the offer) were excluded as there were no candidates who declined the kidney with whom they could be compared. A total of 100 959 candidates who declined the IRD offers were identified as matched controls.
Candidates were followed from the date of transplant (for those who accepted) or the date of the IRD offer decline (for those who declined) until date of death or administrative censoring on T A B L E 1 Characteristics of candidates on whose behalf IRD kidneys were accepted or declined between December 25, 2009 and January 6, 2015
were considered to have had a time-varying exposure, with timeat-risk between the decline and the acceptance contributing to the decline risk set, and subsequent time-at-risk contributing to the accept risk set. In other words, these candidates were censored at the date of IRD kidney transplant and entered into the IRD acceptance risk group to be followed forward from the date of IRD transplant.
Candidates who declined multiple IRD kidneys were included as independent matched controls for each IRD declined. We applied weights to the matched controls to ensure equality in the sum of the weights for candidates who accepted or declined each IRD kidney.
To account for different demographic and clinical characteristics of candidates who accepted or declined the IRD kidney offers, we adjusted the final model for candidate blood type, time on dialysis, age at time of offer, race, sex, cPRA, and diagnosis (categorized as glomerulonephritis, diabetes, hypertension, and other). Finally, to determine whether the survival benefit of IRD acceptance varied by center wait time, we tested the interaction between accepting an IRD and the median time-to-transplantation of the candidate's center in the model.
| Time-varying hazard of IRD kidney acceptance
Candidates who accepted the IRD kidney faced a perioperative risk period following transplantation, and those who declined the IRD kidney did not face this perioperative period. As such, the proportional hazards assumption fails, and we must estimate the time-varying nature of the hazard following acceptance of an IRD kidney. We estimated hazard of IRD acceptance within the first 30 days postdecision to capture perioperative risk, between 1 and 6 months postdecision, and beyond 6 months postdecision; these time bins were determined empirically.
| Quality and discard of IRD kidneys
To understand whether high-quality IRD kidneys were being discarded (defined as recovered but not transplanted), we identified 7670 IRD and 51 832 non-IRD kidneys that were used for kidney transplant and we compared the quality of IRD and non-IRD kidneys that were used and the quality of those that were discarded using Wilcoxon rank sum tests. We estimated the relative rate of discard of IRD versus non-IRD kidneys using modified Poisson regression. To determine whether discard of IRD kidneys varied by KDPI, we tested the interaction between the relative rate of discard and categories of KDPI of the recovered kidney; KDPI categories <30, 30-50, 51-70, and 71-100 were determined empirically.
| Sensitivity analysis
To determine whether the use of candidates who declined multiple IRD offers as independently matched controls introduced a bias in our final model, we performed a sensitivity analysis in which, for each candidate who accepted an IRD kidney, we selected a single matched control from those who declined the same kidney. Sampling was done without replacement such that no candidate was a control for more than 1 IRD recipient.
| RESULTS
| Study population
Compared to candidates who declined IRD kidneys, candidates who accepted IRD kidneys were more likely to be white (42.3%
vs 39.3%, P < .001), have glomerulonephritis (20.0% vs 18.6%, P < .001), and be highly sensitized (cPRA≥80: 14.6% vs 9.6%, P < .001) ( Table 1 The percent of candidates who accepted an IRD offer increased slightly over the study period such that 3.5%, 6.6%, 6.9%, 5.8%, and 7.8% of candidates accepted IRD offers in each year of the study, respectively. 
| Consequences of declining an IRD kidney
| Survival benefit of IRD kidney acceptance
Those who accepted IRD kidneys experienced a perioperative risk period within 30 days postacceptance, with a 2-fold higher risk of death compared to those who declined the IRD offer (adjusted hazard ratio [aHR] 1.22 2.06 3.49 , P < .01) ( Table 2 ). This elevated hazard translated to a crude mortality of 0.8% among those who accepted the IRD offer and 0.4% among those who declined the IRD offer compared to those who declined the IRD (Table 2) . Five years postdecision, crude mortality was 14.0% among those who accepted the IRD offer and 22.5% among those who declined (Figure 3 , P < .001).
The interaction between center median time to transplantation and the survival benefit of accepting an IRD was not statistically significant (P = .8), indicating that the survival benefit incurred by accepting an IRD transplant did not vary by center-level differences in time-to-transplantation.
| Quality and discard of IRD kidneys
Over the study period, IRD and non-IRD kidneys accepted for F I G U R E 3 Patient mortality among those who accepted vs declined the IRD kidney offer. Candidates matched on IRD kidney offer. Within the first 30 days postdecision, mortality was 0.8% and 0.4% for those who accepted vs declined the IRD offer, respectively. Five years postdecision, mortality was 14.0% and 22.5% among those who accepted vs declined the IRD offer, respectively. IRD, increased risk for disease transmission
| Sensitivity analysis
In an analysis that matched without replacement, our inferences with respect to the survival benefit of accepting an IRD kidney were consistent with the main model (aHR within 30 days: 1.46 2.64 4.78 , P = .001; aHR from 1 to 6 months: 0.51 0.69 0.94 , P = .02; and aHR beyond 6 months: 0.47 0.53 0.60 , P < .001).
| DISCUSSION
In this national study, we found that acceptance of an IRD kidney was associated with long-term survival benefit when compared to declining the IRD offer. Candidates who accepted IRD kidney offers experienced a 48% reduced risk of death that continued beyond 6 months after the decision to accept the IRD kidney. Among candidates who declined IRD kidneys, only 31% of candidates received non-IRD kidney transplants within 5 years of the IRD decline, and they accepted non-IRD kidneys with significantly higher KDPI than the IRD kidney they had declined. Finally, we found that IRD kidneys were more likely to be discarded than non-IRD kidneys across KDPI; however, IRD kidneys with KDPI 30-50 faced the highest relative rate of discard at 2.17 times the rate of comparable non-IRD kidneys.
By definition, IRD kidneys are associated with an increased risk of infection, around 1 in 1000 risk of hepatitis C virus (HCV) and 1 in 10 000 risk of HIV. 5, 6 The estimated risk of infection also varies by the criterion for which the donor was labeled IRD, with injection drug users posing the highest HCV risk at 32.4 per 10 000, men who have sex with men at 3.5 per 10 000, and hemophiliac donors at 0.027 per 10 000. 5 One study of IRD recipients has shown higher mortality in IRD as compared to SCD recipients 14 ; however, this analysis was ; however, our analysis showed that the benefit of IRD kidneys remained significant after adjustment for recipient characteristics and that it did not depend on center wait time. The benefit of IRD kidneys despite candidate factors is likely related to the high quality of each offer. While other studies aim to demonstrate the benefit of kidneys known to be associated with worse outcomes, IRD kidneys in our study had a median KDPI of 30, and were more likely to be recovered from younger, healthier donors. 1,12 Additionally, we were able to more accurately estimate survival benefit by identifying the population of candidates who were offered IRD kidneys. Previous analyses of survival benefit were limited to using candidates who remained on the waitlist as the comparison group, 18, 19 whereas patients who received the marginal kidney offer and turned it down are likely different from candidates who might not have received the offer at all.
We also found that 34% of the pool of discarded IRD kidneys have KDPI <50, and that IRD kidneys face a 1. 22 and it further supports the current discourse on improving utilization of these organs.
20, 23-25
It is important to note that our survival benefit analysis included only IRD kidneys that were eventually transplanted. However, given the lengthy kidney transplant waitlist, continued poor outcomes of candidates who remain waitlisted, and the increase in available IRD kidneys driven by the national drug overdose epidemic, 10 it is reasonable to believe that this analysis underestimates the benefits provided by IRD kidneys for candidates on the waitlist 26 and that increased utilization of these kidneys could improve waitlist outcomes.
Our study has several limitations that merit discussion. While our prior simulation of survival benefit did show that benefit varied with specific risk category of the donor, 15 our ability to determine such differences in the current study is limited by the granularity of our data.
However, the rates of disease transmission following IRD transplant are low, 5, 6 and thus the unmeasured rates of disease transmission are unlikely to change the main inferences of our survival benefit analysis. Our use of candidates who declined an IRD offer as the matched controls for the transplanted candidate might be confounded by indication if there are unmeasured differences in the health of patients who accepted or declined IRD kidney offers. However, our use of candidates who declined the same IRD kidney allowed for the closest approximation of the counterfactual in this estimation of survival benefit.
We have found that accepting an IRD kidney was associated with long-term survival benefit, and we have quantified the potential consequences of declining an IRD kidney that patients and providers need 
